RHD and RHCE genotyping by next-generation sequencing is an effective strategy to identify molecular variants within sickle cell disease patients.

MLA

Dezan, Marcia R., et al. “RHD and RHCE Genotyping by Next-Generation Sequencing Is an Effective Strategy to Identify Molecular Variants within Sickle Cell Disease Patients.” Blood Cells, Molecules & Diseases, vol. 65, June 2017, pp. 8–15. EBSCOhost, https://doi.org/10.1016/j.bcmd.2017.03.014.

APA

Dezan, M. R., Ribeiro, I. H., Oliveira, V. B., Vieira, J. B., Gomes, F. C., Franco, L. A. M., Varuzza, L., Ribeiro, R., Chinoca, K. Z., Levi, J. E., Krieger, J. E., Pereira, A. C., Gualandro, S. F. M., Rocha, V. G., Mendrone-Junior, A., Sabino, E. C., & Dinardo, C. L. (2017). RHD and RHCE genotyping by next-generation sequencing is an effective strategy to identify molecular variants within sickle cell disease patients. Blood Cells, Molecules & Diseases, 65, 8–15. https://doi.org/10.1016/j.bcmd.2017.03.014

Chicago

Dezan, Marcia R, Ingrid Helena Ribeiro, Valéria B Oliveira, Juliana B Vieira, Francisco C Gomes, Lucas A M Franco, Leonardo Varuzza, et al. 2017. “RHD and RHCE Genotyping by Next-Generation Sequencing Is an Effective Strategy to Identify Molecular Variants within Sickle Cell Disease Patients.” Blood Cells, Molecules & Diseases 65 (June): 8–15. doi:10.1016/j.bcmd.2017.03.014.